

Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage

Ivan Angulo ^{1,†}, Oscar Vadas ^{2,†,#}, Fabien Garçon ^{3,†}, Edward Banham-Hall ^{3,†}, Vincent Plagnol ⁴, Timothy R. Leahy ^{5,6}, Helen Baxendale ⁷, Tanya Coulter ^{6,8}, James Curtis ¹, Changxin Wu ¹, Katherine Blake-Palmer ¹, Olga Perisic ², Deborah Smyth ⁹, Mailis Maes ¹, Christine Fiddler ¹, Jatinder Juss ¹, Deirdre Cilliers ¹⁰, Gašper Markelj ¹¹, Anita Chandra ⁷, George Farmer ¹², Anna Kielkowska ¹³, Jonathan Clark ¹³, Sven Kracker ^{14,15}, Marianne Debré ¹⁶, Capucine Picard ^{15,16,17}, Isabelle Pellier ¹⁸, Nada Jabado ¹⁹, James A. Morris ²⁰, Gabriela Barcenás-Morales ²¹, Alain Fischer ^{14,15,16}, Len Stephens ³, Phillip Hawkins ³, Jeffrey C. Barrett ²⁰, Mario Abinun ⁵, Menna Clatworthy ¹, Anne Durandy ^{14,15,16,17}, Rainer Doffinger ⁷, Edwin Chilvers ¹, Andrew J. Cant ⁵, Dinakantha Kumararatne ⁷, Klaus Okkenhaug ³, Roger L. Williams ², Alison Condliffe ^{1,‡}, and Sergej Nejentsev ^{1,‡,*}

¹Department of Medicine, University of Cambridge, Cambridge, UK ²Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK ³The Babraham Institute, Cambridge, UK ⁴University College London Genetics Institute, University College London, London, UK ⁵Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK ⁶Our Lady's Children's Hospital, Crumlin, Dublin, Ireland ⁷Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK ⁸Department of Immunology, School of Medicine, Trinity College Dublin, Ireland ⁹Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK ¹⁰Department of Clinical Genetics, Oxford University Hospitals, Oxford, UK ¹¹Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Center, Ljubljana, Slovenia ¹²Raigmore Hospital, Inverness, UK ¹³Babraham Bioscience Technologies Ltd, Babraham Research Campus, Cambridge, UK ¹⁴National Institute of Health and Medical Research INSERM U768, Necker Children's Hospital, F-75015 Paris, France ¹⁵Descartes-Sorbonne Paris Cité University of Paris, Imagine Institute, France ¹⁶Department of Immunology and Hematology, Assistance Publique-Hopitaux de Paris, Necker Children's Hospital, F-75015 Paris, France ¹⁷Center for Primary Immunodeficiencies (CEDI), Assistance Publique-Hopitaux de Paris, Necker Children's Hospital, F-75015 Paris, France ¹⁸Department of Pediatrics, Centre Hospitalier F-49000 Angers France

families, but not among 3,346 healthy subjects. APDS was characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased IgM and reduced IgG2 levels in serum and impaired vaccine responses. The E1021K mutation enhanced membrane association and kinase activity of p110 λ . Patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein and were prone to activation-induced cell death. Selective p110 λ inhibitors IC87114 and GS-1101 reduced the activity of the mutant enzyme in vitro, suggesting a therapeutic approach for patients with APDS.

Respiratory infections are the most common illnesses of people worldwide. Recurrent respiratory infections may lead to bronchiectasis, a permanent, abnormal dilation of bronchi (1). Susceptibility to recurrent respiratory infections and bronchiectasis may be conferred by an underlying primary immunodeficiency (PID) (1, 2). PIDs have variable penetrance and those that have a milder course may remain undiagnosed. Mutations in more than 200 genes are known to cause various PIDs (3). Recent improvements in DNA sequencing technology provide an opportunity to study the patient's whole genome or its coding part, known as the exome (4). This technological advancement has significantly improved the genetic diagnostics of PIDs in patients with recurrent and severe infections and facilitated the identification of novel causative genes and mutations.

We used exome sequencing to search for causative mutations in 35 PID patients from the UK who suffered recurrent infections and had a family history of susceptibility to infections (5). Following identification of genetic variants in these patients, we excluded common polymorphisms previously detected in the 1,000 Genomes and NHLBI projects (table S1) (5). When cross-checking the remaining rare variants, we noted that three patients from one family (P1, P2 and P3 in family A) and one patient from another family (P5 in family B) had the same heterozygous G to A mutation at position 9,787,030 on chromosome 1, c.3061G>A in the PIK3CD gene (fig. 1). This mutation was not present in the other exomes and was the only rare variant shared among all patients in these two unrelated families. It encodes an amino-acid substitution, a glutamic acid for a lysine, at position 1021 (E1021K) of the p110 λ protein, the catalytic subunit of phosphoinositide 3-kinase λ (PI3K λ). Sanger sequencing confirmed the presence of the E1021K mutation in these patients and four additional affected family members. In both families the mutation co-segregated with the clinical phenotype (fig. 1).

We then designed a genotyping assay for this E1021K mutation and screened 3,346 healthy subjects, including 2,296 from the UK and 1,050 representing 51 different populations from around the world (5). No healthy carriers of E1021K were identified in these two large cohorts, supporting our hypothesis that this is a pathogenic mutation rather than a rare neutral polymorphism. We then studied DNA samples of an additional heterogeneous cohort of 134 PID patients from the UK and Ireland (5). In this cohort we identified five further patients from three unrelated families C, D and E who had the same heterozygous E1021K mutation (fig. 1A). The apparent high frequency of the mutation among PID patients and the fact that P8 (family C) had previously been diagnosed with hyper-IgM syndrome prompted us to study an additional cohort from France comprising 15 hyper-IgM patients from 13 families that had previously undergone exome sequencing. Among these we found three patients from two unrelated families F and G with the same mutation, indicating that E1021K may cause a typical hyper-IgM syndrome. One additional patient was identified among family members, bringing the overall number of patients with the E1021K mutation to 17.

Sequencing of the healthy parents of P8 in family C showed that both were homozygous for the normal allele (fig. 1A). Genome-wide identity-by-descent analysis in family C

that stronger binding to membranes contributes to the increased activity of the mutant p110^{E1021K} protein. Another potential activating mechanism of E1021K may involve interaction of p110 with the regulatory subunit p85^Y (14). Our structural model shows that E1021K may impair binding of p110 to the inhibitory cSH2 domain (fig. 2D) leading to increased PI3K activity. However, it is unlikely to affect binding of another inhibitory p85^Y domain, nSH2 (fig. 2D). This is consistent with our observation that pY stimulation further activates the mutant enzyme, probably by removing the nSH2 inhibition.

PI3K is expressed predominantly in cells of hematopoietic lineage and is the major PI3K isoform signaling downstream of T and B cell antigen receptors (TCR and BCR), Toll-like receptors (TLRs), co-stimulatory molecules and cytokine receptors in T, B and myeloid cells (15). Therefore, we studied the activity of the mutant PI3K *ex vivo* in patients' leukocytes. We measured levels of pY using a high-performance liquid chromatography \pm mass spectrometry-based assay (16) in CD4⁺ and CD8⁺ T cells isolated from fresh peripheral blood. In both T lymphocyte lineages we found consistently higher levels in patients than in controls prior to stimulation and 10, 20, 30 and 60 seconds after stimulation (fig. 3A). In patient cells treated with IC87114 the levels of pY were significantly reduced (fig. 3A). Furthermore, in stimulated patients' T cells we found increased levels of phosphorylated AKT protein, a major downstream mediator of signaling (fig. 3B). Levels of p110 expression were normal in the patients' T cells (fig. 3B). We then cloned in a retroviral vector the wild-type p110, the mutant p110^{E1021K} and p110^{D911A} with mutation D911A that inactivates the kinase domain, and transduced these constructs into T blasts isolated from the p110-knockout mouse (5). After stimulation cells with p110^{E1021K} had more phosphorylated AKT than other cells (figs. 3C and S4). Together, these results strongly suggest that the E1021K mutation increases PI3K signaling in vivo as well as in vitro.

To study T cell responses we stimulated purified CD4⁺ and CD8⁺ cells with anti-CD3 and anti-CD28 antibodies. Unexpectedly, we observed that both T cell lineages from patients were prone to cell death (figs. 3D and S5A). This phenomenon was reversed by the addition of IC87114 but not IL-2 (figs. 3D and S5B), suggesting that it is caused by the increased PI3K activity. Cytokine production following stimulation of T cells was profoundly reduced in the patients and was not rescued by exogenous IL-2 (fig. S6), suggesting that T cell death occurs prior to any significant cytokine response. However, stimulation with CytoStim, which did not induce T cell death, also led to reduced cytokine production by the patients-derived T cells (fig. S7). The propensity to activation-induced cell death (AICD) is consistent with T cell lymphopenia found in our patients. It may relate in part to the increased proportion of T cells with an activated/memory phenotype (table S2) (17). Moreover, given that p110 inhibitor reduces AICD of the patient-derived T cells, the activated p110 may increase the AICD per se, possibly by enhancing TCR signalling.

In the patients' B lymphocytes we also found increased amounts of phosphorylated AKT, both before and after stimulation, although this analysis was complicated by enhanced protein degradation in the patient-derived cells (fig. S8). Studies in transgenic mice deficient for phosphatase and tensin homologue (PTEN), an enzyme that dephosphorylates pY, have shown that PI3K activity, pY and phosphorylated AKT suppress immunoglobulin class switch recombination (CSR) in B cells. These mice have impaired B cell function, increased IgM, decreased IgG and IgA levels and impaired antibody responses after immunization (18-21). Immunological presentation of our patients resembles this phenotype and indicates a B cell defect. However, normal total IgG and IgA levels that were found in most of our patients suggest that CSR may be only partially affected. Nevertheless, inefficient antibody production impairs responses to *S. pneumoniae* and *H. influenzae* type B vaccinations in our patients leading to recurrent infections with these pathogens. An increased population of

circulating transitional B cells may reflect a block in late stages of B cell maturation or an enhanced death of mature B cells.

PI3K γ is also highly expressed in neutrophils. We found that patient-derived neutrophils retained their ability to undergo a respiratory burst, degranulation, chemotaxis, and apoptosis (fig. S9). We measured pAkt accumulation in TNF γ -primed neutrophils in response to fMLP stimulation at 6 seconds (a PI3K γ -dependent response) and at 60 seconds (a predominantly PI3K γ -mediated signal) (22) and found no significant difference between patients and controls in either response (fig. S9). Thus, the effect of the E1021K mutation on the PI3K γ activity may be cell-type or stimulus-specific, or may be compensated for by effects of other PI3K isoforms or PTEN. Nevertheless, we cannot exclude that a subtle defect in neutrophil function may contribute to the disease pathogenesis in these patients.

Here we describe a PID caused by a recurrent autosomal dominant germline mutation E1021K in the PIK3CD gene that encodes p110 γ . We found it in 17 patients from seven unrelated families, suggesting that it is frequent among PID patients and may explain a substantial fraction of patients with recurrent respiratory infections and bronchiectasis. Our rapid genotyping assay should facilitate screening for the E1021K mutation in existing PID and bronchiectasis cohorts, as well as new patients. The E1021K mutation was previously noted in one Taiwanese patient with recurrent respiratory infections and PID; however, its causative and pathogenic role has not been demonstrated (23). Here we have shown that E1021K increases PI3K γ activity, augmenting the production of IP_3 and activating the downstream AKT protein in lymphocytes. This leads to defects in T and B cell function and inefficient immune responses to bacterial pathogens, predisposing to recurrent respiratory infections and eventually to bronchiectasis. We named this disorder Activated PI3K-Delta Syndrome (APDS).

Activation of the PI3K pathway is associated with malignant transformations and it has been shown that overexpression of p110 γ can transform cells (24). To date, only one of our APDS patients, P13, has been diagnosed with lymphoma (table 1). Nonetheless, the oncogenic potential of PI3K up-regulation can be enhanced by additional mutations (25, 26). Therefore, APDS patients may be at increased risk of leukemia or lymphoma if they acquire additional somatic mutations.

The APDS patients described here had been treated with immunoglobulin replacement and antibiotics. Despite this, there is evidence of significant airway damage in most cases. Because of progressive severe disease following splenectomy, patient P8 underwent allogeneic hematopoietic stem cell transplantation (HSCT) at the age of 8 years. One year after HSCT his clinical condition had improved dramatically, suggesting that HSCT may be a long-term treatment option for young patients. Nevertheless, our results raise the possibility that selective p110 γ inhibitors, such as GS-1101, may be an alternative effective therapeutic approach in APDS patients. GS-1101 (CAL-101 or Idelalisib) has been tested in phase I/II clinical trials for treatment of chronic lymphocytic leukemia (www.clinicaltrials.gov). The possibility of treating APDS patients with p110 γ inhibitors should therefore be considered.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477 and the EU FP7 collaborative grant 261441

(PEVNET project). S.N., A.C., D.K., and R.D. are supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. O.V. was supported by a Swiss National Science Foundation fellowship (grant no. PA00P3_134202) and a European Commission fellowship (FP7-PEOPLE-2010-IEF, no. 275880). R.L.W

19. Suzuki A, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. *J Exp Med*. 2003; 197:657. [PubMed: 12615906]
20. Omori SA, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. *Immunity*. 2006; 25:545. [PubMed: 17000121]
21. Janas ML, et al. The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells. *J Immunol*. 2008; 180:739. [PubMed: 18178811]
22. Condliffe AM, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. *Blood*. 2005; 106:1432. [PubMed: 15878979]
23. Jou ST, et al. Identification of variations in the human phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of unknown aetiology. *Int J Immunogenet*. 2006; 33:361. [PubMed: 16984281]
24. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A*. 2006; 103:1289. [PubMed: 16432180]
25. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer*. 2009; 9:550. [PubMed: 19629070]
26. Kinross KM, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. *J Clin Invest*. 2012; 122:553. [PubMed: 22214849]
27. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007; 447:661. [PubMed: 17554300]
28. Power C, Elliott J. Cohort profile: 1958 British birth cohort (National Child Development Study). *Int J Epidemiol*. 2006; 35:34. [PubMed: 16155052]
29. Cann HM, et al. A human genome diversity cell line panel. *Science*. 2002; 296:261. [PubMed: 11954565]
30. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012; 491:56. [PubMed: 23128226]
31. Fu W, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature*. 2013; 493:216. [PubMed: 23201682]
32. Berndt A, et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. *Nat Chem Biol*. 2010; 6:244. [PubMed: 20154668]
33. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:486. [PubMed: 20383002]
34. Wehr C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. *Blood*. 2008; 111:77. [PubMed: 17898316]
35. Clayton E, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. *J Exp Med*. 2002; 196:753. [PubMed: 12235209]
36. Revy P, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell*. 2000; 102:565. [PubMed: 11007475]
37. Hayward AR, Mowla R, Harvey B. Defect of neutrophil mobility with dominant inheritance in a family with Waardenberg's syndrome. *Arch Dis Child*. 1981; 56:279. [PubMed: 7247439]

Fig. 1. Families with the E1021K p110 \ mutation
(A) ÷ and Í - unaffected; ô and ì - affected, ● and ■ - available data indicate recurrent infections. Age at the time of death is shown for patients who died < 30 years of age.
PIK3CD

Fig. 2. *In vitro* activity and structure of p110 \

(A) Basal and pY-stimulated PI3K activity at 20 nM concentration. Graphs are mean \pm SD of 3 independent experiments. P-values were calculated by two-tailed t-test. (B) Inhibition of mutant and wild-type p110 \ p85 Y as a function of IC87114 or GS-1101 concentration (data are mean \pm SD, N=3). (C) Domain organization of p110 \. (D) Structural model of the p110 \ p85 Y heterodimer. p110 \ catalytic subunit (pale green), nSH2 and iSH2 domains of the p85 regulatory subunit (cyan), cSH2 domain (magenta), p110 \ activation loop (thick chocolate tube beneath k Y12), residue E1021 of p110 \ (green spheres) and the analogous residue in H1047R mutant of p110 Y (cyan spheres). The IC87114 inhibitor bound in the active site is shown in stick representation. (E) Membrane binding of p110 \. FRET between the PI3K complex and Dansyl-PS-containing membrane vesicles in the absence (solid lines) or presence (dashed lines) of the pY peptide (data are mean \pm SD, N=3).

Fig. 3. Functional analyses of T cells in patients with APDS
(A) Intracellular PIR₃ levels in CD4+ and CD8+ T lymphocytes of patients (red squares, N=6) and controls (blue circles, N=5) at indicated times after anti-CD3/anti-CD28 stimulation in the presence or absence of IC87114. The data are expressed as the ratio of the quantity of PIR₃ divided by that of the internal standard (ISD) and normalized according to the cell number. The data show mean +/- SEM. P-values were calculated using two-way ANOVA with Bonferroni correction.

Table 1
Summary of clinical and immunological features of patients with the E1021K p110 \ mutation

Clinical / Immunological manifestation	Patients	Frequency, n / total studied (%)
Recurrent respiratory and ear infections (H. influenzae, S. pneumoniae)	P1-17	17/17 (100)
CT evidence of large (bronchiectasis) or small (mosaic attenuation) airway disease	P1-7,9,11-13,17	12/16 (75)
Splenomegaly (prior to the onset of recurrent infections)	P2,3,5,6,8,9,13-16	10/17 (59)
Skin, salivary gland, lacrimal gland or dental abscess formation, orbital cellulitis	P1,3,5-8,10	7/17 (41)
Infection caused by herpes group viruses (HSV, CMV, VZV, EBV)	P3,8,12,13 (and the deceased sister of P5/P6)	4/17 (24)
Marginal zone lymphoma	P13	1/17 (6)
Low/intermittent low serum IgG2 levels	P2-7,10-13	10/11 (91)
High/intermittent high serum IgM levels	P1-6,8-11,13-16	14/17 (82)
Low levels of anti-pneumococcal antibodies	P1-4,7,9,11-13,17	10/10 (100)
Low levels of anti-Haemophilus Influenzae type B antibodies	P1-4,8,9,12,13	8/10 (80)
Decreased circulating T cells (total CD3+) and/or CD4+ and/or CD8+ T cells	P1-9,13,14,17	12/17 (71)
Decreased circulating B cells (total CD19+)	P2-9,13,14-16	12/17 (71)
Increased circulating transitional B cells (CD19+CD38+IgM+)	P1-4,7-14,16,17	14/16 (88)
Decreased circulating class switched memory B cells (CD19+CD27+IgD)	P1-3,8,9,12,13,16	8/16 (50)